Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
08 févr. 2024 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Provides 2024 Financial Guidance
03 janv. 2024 08h00 HE
|
Collegium Pharmaceutical, Inc.
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA*...
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
27 nov. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of...
Collegium Announces $25 Million Accelerated Share Repurchase Program
09 nov. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Upcoming Investor Conferences
08 nov. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Third Quarter 2023 Financial Results
07 nov. 2023 16h01 HE
|
Collegium Pharmaceutical, Inc.
– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up...
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
24 oct. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
28 août 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
24 août 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces $50 Million Accelerated Share Repurchase Program
07 août 2023 07h30 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...